H9 Priming Study in Healthy Adults
Summary
The purpose of this research study is to determine whether prior exposure to A/H2N2 viruses is associated with better antibody (part of the immune system that fights infection) responses after vaccination with an A/H9N2 flu vaccine. The study will evaluate how much antibody is made to the influenza virus after H9N2 flu vaccination and how the body reacts to different strengths of the H9N2 flu vaccine. This information may guide vaccine development for this virus as well as other bird flu viruses that have infected humans. Study participants will include 120 healthy subjects, age 18-38 or 44-59 years. Two different dosages of vaccine will be given in the muscle of the upper arm about 1 month apart. The assignment of vaccines to participants is governed by chance. Study procedures may include medical history, physical exam, and blood samples. Study participation duration is about 7 months.
Timeline
- Start
- 2008-02
- Primary completion
- 2008-08
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine | Vaccine | 7.5 ug | Intramuscular |
| Subject | Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine | Vaccine | 30 ug | Intramuscular |